- Home
- IMAB vs OPTN Comparison
IMAB vs OPTN Comparison
Compare IMAB & OPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- OPTN
- Stock Information
- Founded
- IMAB 2014
- OPTN 2010
- Country
- IMAB United States
- OPTN United States
- Employees
- IMAB N/A
- OPTN N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- OPTN Biotechnology: Pharmaceutical Preparations
- Sector
- IMAB Health Care
- OPTN Health Care
- Exchange
- IMAB Nasdaq
- OPTN Nasdaq
- Market Cap
- IMAB 79.9M
- OPTN 55.4M
- IPO Year
- IMAB 2020
- OPTN 2017
- Fundamental
- Price
- IMAB $0.84
- OPTN $5.37
- Analyst Decision
- IMAB Strong Buy
- OPTN Strong Buy
- Analyst Count
- IMAB 3
- OPTN 3
- Target Price
- IMAB $8.00
- OPTN $16.67
- AVG Volume (30 Days)
- IMAB 216.1K
- OPTN 18.0K
- Earning Date
- IMAB 03-21-2025
- OPTN 03-25-2025
- Dividend Yield
- IMAB N/A
- OPTN N/A
- EPS Growth
- IMAB N/A
- OPTN N/A
- EPS
- IMAB N/A
- OPTN N/A
- Revenue
- IMAB $569,464.00
- OPTN $75,672,000.00
- Revenue This Year
- IMAB N/A
- OPTN $13.42
- Revenue Next Year
- IMAB N/A
- OPTN $38.54
- P/E Ratio
- IMAB N/A
- OPTN N/A
- Revenue Growth
- IMAB N/A
- OPTN 5.13
- 52 Week Low
- IMAB $0.76
- OPTN $4.82
- 52 Week High
- IMAB $2.00
- OPTN $31.50
- Technical
- Relative Strength Index (RSI)
- IMAB 38.53
- OPTN 43.29
- Support Level
- IMAB $0.78
- OPTN $5.11
- Resistance Level
- IMAB $0.93
- OPTN $5.56
- Average True Range (ATR)
- IMAB 0.07
- OPTN 0.41
- MACD
- IMAB -0.01
- OPTN 0.01
- Stochastic Oscillator
- IMAB 33.45
- OPTN 23.89
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.